Fig. 8: DFMO affects neuroblastoma viability and MYCN expression but does not enhance differentiation-inducing potential of ATRA. | Cancer Gene Therapy

Fig. 8: DFMO affects neuroblastoma viability and MYCN expression but does not enhance differentiation-inducing potential of ATRA.

From: The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme

Fig. 8: DFMO affects neuroblastoma viability and MYCN expression but does not enhance differentiation-inducing potential of ATRA.

SK-N-BE(2)-C, Kelly, and SK-N-AS cells were treated with 5 mM DFMO, a well-studied ODC1 inhibitor, combined with 1 μM ATRA for 6 days. A Relative viability of those cells was measured by CellTiter Glo. B MYCN protein level was assessed in SK-N-BE(2)-C. C Cell morphology was observed via brightfield microscope. All the experiments were performed in triplicates and a representative result or mean is shown; error bars show standard deviation.

Back to article page